EU Pharma Strategy Will Remove Barriers And Bolster Competition
Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
You may also be interested in...
Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic.
EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.
European policy makers must act quickly to harness the benefits of biosimilars as part of the new EU Pharma Strategy, Medicines for Europe insists in the wake of the latest annual report on European biosimilar competition.